Hologenomix B.V.
Hologenomix makes non-invasive DNA testing accessible by extracting cell-free DNA from urine for molecular diagnostics. The company uses cell-free DNA extraction technology from biofluids to isolate cfDNA suitable for analysis and supports applications in liquid biopsy. This biotech startup focuses on B2B opportunities in cancer detection, transplant monitoring, and personalized medicine. Its approach integrates with standard laboratory workflows and supports scalable, high-throughput processing. The technology targets the liquid biopsy market and aims to broaden access to advanced molecular diagnostics.
Hologenomix B.V.
Hologenomix makes non-invasive DNA testing accessible by extracting cell-free DNA from urine for molecular diagnostics. The company uses cell-free DNA extraction technology from biofluids to isolate cfDNA suitable for analysis and supports applications in liquid biopsy. This biotech startup focuses on B2B opportunities in cancer detection, transplant monitoring, and personalized medicine. Its approach integrates with standard laboratory workflows and supports scalable, high-throughput processing. The technology targets the liquid biopsy market and aims to broaden access to advanced molecular diagnostics.